

OSAKA, JAPAN – February 10, 2012 – Nipro Corporation (Head Office: Osaka, Japan) announced today the completion of the acquisition of the Liebmann Group, Műnnerstadt, Germany.

The acquisition of the Liebmann Group, known commercially as *MGlas AG* and *MG STERILE PRODUCTS AG* is part of Nipro's strategy to develop its glass business internationally. In addition to a regional expansion, the acquisition allows for a significant portfolio expansion. The Liebmann Group brings state-of-the-art sterile and non-sterile pharmaceutical glass packaging, including syringe manufacturing, to the European glass activities of Nipro.

Kurt van Dal, current President and CEO of Nipro Europe, Nipro Glass Belgium, Nipro Glass France and Nipro Glass Americas has been given the additional role of President of the board of the newly added organizations.

"This most recent acquisition is another step for Nipro to become a strong player in the glass business" said Mr. Van Dal. "*MGlas AG* and *MG STERILE PRODUCTS AG* add qualitative products and skilled people to our global glass organization, as well as key expansion to our product portfolio with amongst others sterile and non-sterile glass syringes.

This addition, in combination with our expertise on glass and the existing network of customers will consolidate our position as a challenger for the current market leader and a privileged partner for our customers worldwide."

About Nipro Corporation:

Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), founded in 1954, is engaged directly and through its subsidiaries principally in the development, manufacture and sale of medical devices, pharmaceutical products and glass products. Nipro's medical device division is engaged in the manufacture and sale of medical devices and its related products, the development, manufacture and sale of cell culturing-related products, as well as the development and sale of products related to diabetes. Nipro's pharmaceutical division is engaged in the research, manufacture and sale of pharmaceuticals, such as blood derivatives. The Nipro Glass division, through its global implementation, is a vertically integrated manufacturer of high quality glass for pharmaceutical and niche applications. Nipro and its subsidiaries also sell medical device manufacturing equipment and conduct real estate leasing and non-life insurance agency businesses.

For more information please visit www.nipro.co.jp or www.nipro-europe.com.